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Abstract
Despite the identification of acquired genetic mutations associated with Myeloproliferative Neoplasms (MPNs) there is a paucity of
information relating to modifiable risk factors that may lead to these mutations. The MOSAICC Study was an exploratory case-control
study of polycythemia vera (PV), essential thrombocythemia (ET), and Myelofibrosis (MF). MPN patients and population controls
(identified by General Practitioners) and non-blood relative/friend controls were recruited from 2 large UK centers. Participants
completed a telephone-based questionnaire analyzed by unconditional logistic regression analysis adjusting for potential
confounders. Risk factors for MPNs identified included increasing childhood household density [odds ratio (OR) 2.55, 95%
confidence interval (CI) 1.16–5.62], low childhood socioeconomic status (OR 2.30, 95%CI 1.02–5.18) and high pack years smoking
(OR 2.19, 95%CI 1.03–4.66) and current smoking restricted to JAK2 positive PV cases (OR 3.73, 95%CI 1.06–13.15). Obesity was
linked with ET (OR 2.59, 95%CI 1.02–6.58) confirming results in previous cohort studies. Receipt of multiple CT scans was
associated with a strongly increased risk of MPN although with wide confidence intervals (OR 5.38, 95%CI 1.67–17.3). Alcohol intake
was inversely associated with risk of PV (OR 0.41, 95%CI 0.19–0.92) and ET (OR 0.48, 95%CI 0.24–0.98). The associations with
childhood household density, high pack years smoking and alcohol were also seen in multivariate analysis. This is the largest case
control study in MPNs to date and confirms the previously reported associations with obesity and cigarette smoking from cohort
studies in addition to novel associations. In particular, the role of smoking and JAK2 mutation cases merits further evaluation.
Introduction
Myeloproliferative neoplasms (MPNs) are a group of rare
hematopoietic malignancies characterized by stem cell-derived
clonal proliferation of myeloid lineages. Reported incidence rates
varywith our recent systematic review reporting pooled incidence
rates for polycythemia vera (PV), essential thrombocythemia
(ET) and primary myelofibrosis (PMF) of 0.84, 1.03 and 0.47 per
100,000, respectively.1 In these Ph-negative MPN cases, referred
to as classic MPNs, an acquired genetic mutation of Janus kinase
2 (JAK2)v617F is present in almost all PV patients and
approximately 50% ET and PMF patients.2 Other acquired
mutations, including myeloproliferative leukemia virus oncogene
codon 515 (MPL)3 and Calreticulin (CALR)4,5 have been
identified. Inherited defects in DNA repair increase the risk of
hematopoietic neoplasms.6–8 DNA repair genes, for example,
XRCC1 and other genes shown to be environmentally sensitive
(NAT2, CYP1A2, GSTA1, and GSTM3) have been associated
with MPN,9 suggesting that environmental carcinogens may be
involved in their development and the acquisition of acquired
mutations.
Our research group lead a systematic review which identified
limited etiological studies for the classic MPNs.10 Seven case-
control studies with sample sizes ranging from 9 to 93 MPN
patients11–17 were identified. Potential risk factors identified
included dark hair dye use, blood donation and a variety of
occupational exposures.10 These studies were severely limited by
small sample sizes and/or inability to investigate subtype specific
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risks.11,13 While smoking and alcohol were not associated with
MPNs in these small case control studies,13,17 current smoking,
increasing body mass index (BMI), and lower physical activity
levels were positively associated with some MPN subtypes in
recent cohort studies.18–20 To investigate potential risk factors
further we undertook an exploratory case-control study in the
United Kingdom (UK).
Methods
The exploratory MOSAICC (Myeloproliferative Neoplasms: An
In-depth Case-Control) study aimed to identify appropriate
methodological approaches to roll-out a largeUK-wide case-control
study of MPNs. MPN patients were recruited from 2 sites: Belfast
City Hospital, Belfast and University Hospital Southampton NHS
FoundationTrust, Southampton.Eligiblepatients, identifiedby their
leadconsultant (MFMcMandASD),wereclassifiedaccording to the
WHOdiagnostic criteria.21 A study information packwas provided
containing a consent form, study information booklet and a MPN-
Symptom Assessment Form.22 Patients were asked to recruit non-
blood relative or friend (NBR/F) controls to the study by providing
them with information flyers. Age (5-year age band) and gender
frequency-matched General Practice (GP) controls were also
recruited. Patients were ineligible if they were<18 years of age or
were incapable of giving informed consent or were physically or
cognitively incapable of completing a telephone interview. Partic-
ipants underwent a structured telephone interview (average
interview time: 45 minutes) with a trained interviewer using a
questionnaire designed to identify medical and lifestyle risk factors.
Ethical approval was obtained from the Office for Research Ethics
Committee, Northern Ireland (ORECNI 12/NI/0165).
Data was collected on gender, age (dichotomized to<60 and
≥60 years), recruiting clinic (Belfast/Southampton), ethnicity
(Caucasian vs other) and Jewish ancestry. Childhood socio-
economic position (SEP), based on main household occupation,
was classified using the Standard Occupational Classification
system from highest1 to lowest5 social class.23 Birth order and
number of siblings (termed sibship size) were requested with
childhood household density calculated by dividing the number of
children by the number of bedrooms in the childhood home. Level
of education was categorized as none- GCSE/O-level or A-level or
higher or equivalents. Pack years of smoking was calculated by
dividing average number of cigarettes smoked/day by 20 and
multiplying by years of smoking. Alcohol consumption was
measured by the average number of units of wine, beer or spirits
consumed per week within or above the UK Drinkaware
guidelines.24 Self-reportedweight andheightwereused to calculate
BMI with classification according to the World Health Organiza-
tion criteria (underweight:<18.5kg/m2, normal weight: 18.5–
24.99kg/m2, overweight: 25–29.99kg/m2, obese/severely obese:
≥30kg/m2).25 Questions included self-reported piercings, tattoos,
tooth fillings, implants (metal plates, silicone implants etc.) and
hair dye use. Current information on use and storage of chemicals
within the home in addition to hobbies and air travel was also
obtained. Additionally, a range of pre-existing medical conditions
identified in the systematic review10 was investigated.
Statistical analysis
Variables were compared between GP and NBR/F controls
using unconditional logistic regression. Multivariate logistic
regression models comparing MPN patients to all controls were
adjusted for age, gender and clinic (location) producing adjusted
odds ratios (ORs) and corresponding 95% confidence intervals
(CIs). Tests for trend were used to determine significance per
category increase of the exposure/variable. A backwards stepwise
logistic regression analysis was constructed including associa-
tions significant at p<0.010 to identify key risk factors.
Statistical analyses were performed using STATA 12.0TM
(StataCorp, College Station, TX).
Results
In total, 106MPN cases and 120 controls were included in these
analyses representing overall participation rates of 66.7% and
32.3%, respectively. Rates were much lower in GP vs NBR/F
controls; 17.0% and 72.5%, respectively. After adjustment for
age, gender, clinic and education, GP controls were less likely to be
female (p=0.009), tohave toothfillings (p=0.001) andmore likely
to have asthma (p=0.045) than NBR/F controls. The control
groups did not differ in regard to any of the other exposures
assessed and we therefore combined the 2 groups for analysis.
Mean age did not significantly differ between cases [63.3 years,
standard deviation (SD) 12.5 years] and controls (60.5 years, SD
12.4 years), p=0.093. Compared to all controls MPN cases did
not significantly differ with regard to any of the participant
characteristics reported in Table 1. The distribution of patients
within the 3 subtypes of MPN is shown in Table 2. Of the MPN
cases 71 (67.0%) were JAK2 positive.
Childhood factors
MPN patients were more likely than controls (all or either
subgroup) to have been raised in a household where the main
occupationwas of a lower socio-economic status, (OR 2.30, 95%
CI 1.02–5.18). There was trend for MPN patients to have
Table 1
Demographic Characteristics of Participants
Variable
Controls
n (%)
MPN Cases
n (%)
Unadjusted Odds
ratio (95% CI)
Age group
<60 years 43 (35.8) 33 (31.1) 1.00
≥60 years 77 (64.2) 73 (68.9) 1.24 (0.71–2.15)
Gender
Male 46 (38.3) 42 (39.6) 1.00
Female 74 (61.7) 64 (60.4) 0.95 (0.55–1.62)
Clinic
Southampton 72 (60.0%) 66 (62.3) 1.00
Belfast 48 (40%) 40 (37.7) 0.91 (0.53–1.55)
Ethnicity
Caucasian 116 (96.7) 102 (96.2) 1.00
Other 4 (3.3) 4 (3.8) 1.14 (0.28–4.66)
Jewish
No 119 (99.2) 102 (96.2) 1.00
Yes 1 (0.83) 2 (1.89) 2.33 (0.21–26.11)
Don’t know 0 (0) 2 (0.88) –
Table 2
Distribution of Patients Between the 3 Disease Subtypes
MPN subtype Number %
PV 37 34.9
ET 55 51.9
PMF 14 13.2
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experienced higher childhood household density than controls
(OR 2.55, 95% CI 1.16–5.62), although this trend did not reach
significance, Table 3.
Lifestyle factors
Current cigarette smoking was more common in cases than
controls but statistical significancewas only observed in those who
had the highest pack years of smoking, (OR 2.19 95%CI 1.03–
4.66, p=0.01; Table 4. Current smoking status was significantly
elevated for PV cases only (OR3.73, 95%CI 1.06–13.15) Table 5.
Alcohol consumption was inversely associated with MPNs, in
PV (OR 0.41, 95% CI 0.19–0.92) and ET (OR 0.48, 95% CI
0.24–0.98) but not MF (OR 1.03, 95% CI 0.26–4.11). Risk of
MPNs did not significantly differ by alcohol type consumed; wine
(OR 0.90, 95% CI 0.49–1.64), beer (OR 0.81, 95% CI 0.30–
2.17) and spirits (OR 0.41, 95% CI 0.08–2.21) Tables 4 and 5.
While obesity appeared to elevate overall MPN risk it was not
significant, Table 4. However, when stratified by MPN subtype,
obesity was significantly associated with ET (OR 2.59, 95% CI
1.02–6.58) only, Table 5. There were no significant associations
between piercings, tattoos, implants or hair dying and MPNs,
Table 4.
Environmental factors/other
There were no significant associations between use of potential
household carcinogens and excess MPN risk. Painting in home
decorating was less commonly reported among MPN patients
than controls, (OR 0.44, 95%CI 0.25–0.79) Table 6. The
majority (>90%) of participants had had pets but there was no
significant difference overall between cases and controls (OR
0.90, 95% CI 0.37–2.17). Of all animal types investigated only
pig ownership was higher among cases than controls, 8 (7.5%) vs
2 (1.7%) (OR 5.62, 95% CI 1.13–28.0). Low absolute numbers
precluded further multivariate analysis and larger studies will be
needed to determine whether this is a genuine risk factor.
There were no significant associations seen with a number of
other putative environmental risk factors including the use of
home solvents, paints, bleach, oven cleaner, garden herbicides or
pesticides, frequency of boiler maintenance or home car
mechanical work. Also, no differences between cases and
Table 3
Socioeconomic Position in Childhood and Related Childhood
Exposures in Patients with MPNs) Compared to Controls.
Controls MPN cases
Variable n (%) n (%) OR
∗
(95% CI)
Socio-economic position of head of household as child
1 (highest) 38 (31.7) 16 (15.4) 1.00
2 24 (20.0) 29 (27.9) 2.88 (1.29 -6.44)
3 8 (6.7) 6 (5.8) 1.78 (0.52–6.07)
4 25 (20.8) 28 (26.9) 2.59 (1.16–5.78)
5 (lowest) 25 (20.8) 25 (24.0) 2.30 (1.02–5.18)
p for trend 0.091
Birth Order
Other 72 (60.0) 48 (40.0) 1.00
Firstborn 71 (67.0) 35 (33.0) 0.71 (0.41–1.23)
Sibship size
0/1 50 (41.7) 43 (40.6) 1.00
2 32 (26.7) 23 (21.7) 0.86 (0.44–1.71)
3–4 23 (19.2) 26 (24.5) 1.38 (0.67–2.80)
5 or more 15 (12.5) 14 (13.2) 1.14 (0.49–2.64)
p for trend 0.516
Childhood household density
<1 child/bedroom 28 (23.3) 11 (10.4) 1.00
1 child/bedroom 29 (24.2) 33 (31.1) 3.12 (1.30–7.48)
2 or more children/ bedroom 63 (52.5) 62 (58.5) 2.55 (1.16–5.62)
p for trend 0.069
Attended Nursery/playschool/preschool
No 90 (75.0) 83 (79.1) 1.00
Yes 30 (25.0) 22 (21.0) 0.82 (0.43–1.58)
Education
None- GCSE/O-level 41 (34.2) 48 (45.3) 1.00
A-level or higher 79 (65.8) 56 (52.8) 0.62 (0.36–1.06)
Don’t know 0 (0) 2 (1.9) –
∗
Adjusted for age (5 year age bands), gender, site location (Southampton/Belfast) and education
(category).
Table 4
Lifestyle Risk Factors and Association with Myeloproliferative
Neoplasms (MPN) Compared to Controls.
Controls MPN Cases
Variable n (%) n (%) OR
∗
(95% CI)
Cigarette smoking
Never 69 (57.5) 51 (48.1) 1.00
Former 45 (37.5) 46 (43.4) 1.35 (0.77–2.35)
Current 6 (5.0) 9 (8.49) 2.13 (0.71–6.42)
<20 pack years 35 (29.4) 30 (28.6) 1.14 (0.62–2.10)
≥20 pack years 15 (12.6) 24 (22.9) 2.19 (1.03–4.66)
p for trend (pack years) 0.010
Alcohol
Never 27 (22.5) 41 (38.7) 1.00
Ever 93 (77.5) 65 (61.3) 0.48 (0.27–0.86)
Within Drinkaware guidelines$ 66 (55.0) 48 (45.3) 0.50 (0.27–0.93)
Above Drinkaware guidelines$ 27 (22.5) 17 (16.0) 0.42 (0.19–0.93)
Body mass index (current)
Underweight 2 (1.68) 3 (2.83) 1.96 (0.31–12.3)
Normal 57 (47.9) 44 (41.5) 1.00
Overweight 45 (37.8) 37 (34.9) 1.05 (0.58–1.89)
Obese 15 (12.61) 22 (20.8) 1.97 (0.91–4.25)
p for trend (Norm-Obese) 0.201
Body mass index (10 years)
Underweight 3 (2.54) 2 (1.92) 0.95 (0.15–6.08)
Normal 70 (59.3) 56 (41.5) 1.00
Overweight 40 (33.9) 36 (34.6) 0.96 (0.48–1.95)
Obese 5 (4.24) 10 (9.62) 2.53 (0.85–7.57)
p for trend (Norm-Obese) 0.315
Piercings
No 56 (46.7) 64 (53.3) 1.00
Yes 49 (46.2) 57 (53.8) 1.31 (0.59–2.91)
Tattoos
No 108 (90.0) 99 (93.4) 1.00
Yes 12 (10) 7 (6.6) 0.59 (0.20–1.69)
Tooth Fillings
No 53 (44.2) 36 (34.0) 1.00
Yes 67 (55.8) 70 (66.0) 1.29 (0.75–2.23)
Implants
No 106 (88.3) 90 (84.9) 1.00
Yes 14 (11.7) 16 (15.1) 1.28 (0.58–2.81)
Hair Dye
No 55 (45.8) 51 (48.1) 1.00
Yes 65 (54.2) 55 (51.9) 0.94 (0.42–2.10)
Dark dye 40 (33.3) 36 (34.0) 1.07 (0.55–2.07)
Self-administered 43 (35.8) 28 (26.4) 0.60 (0.31–1.15)
Dyed by someone else 48 (40.0) 46 (43.4) 1.46 (0.71–2.98)
Bleached
No 92 (76.7) 74 (69.8) 1.00
Yes 28 (23.3) 32 (30.2) 1.66 (0.86–3.21)
(2020) 4:1 www.hemaspherejournal.com
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controls were seen in the frequency of short or long haul flights
taken per year.
Medical history
There were no significant associations between any of the
medical conditions (diagnosed before MPN diagnosis) and
MPNs, Table 6. Of the medical procedures investigated only
the frequency of CT scans was associated with an increased risk
of MPNs, Table 6. Patients receiving 3 or more CT scans had OR
of 5.38 (95%CI 1.67–17.3). There was no difference between
cases and controls by any CT sites (data not shown) or by the
proportion of cases having had a CT scan by clinic.MPN patients
and controls reported having had CT scans of their full body (n=
9 cases vs 9 controls), head and neck (n=15 vs 12), back (n=2 vs
3), chest (n=9 vs 4), abdomen (n=18 vs 17), groin (n=3 vs 0)
and legs/arms (n=6 vs 6).
Multivariate model
In the backwards multivariate regression model, smoking >20
pack years, (OR 2.69, 95% CI 1.26–5.74) and childhood
household density (Intermediate vs low: OR 2.35, 95% CI 1.01–
5.45); high vs low: OR 2.34, 95% CI 1.26–5.74) remained
significantly associated with increased risk of MPNs. Alcohol
(OR 0.50, 95%CI 0.27–0.94) and household painting (OR 0.42,
95% CI 0.23–0.76) remained inversely associated with MPNs.
Discussion
In this exploratory case-control study, we confirmed associ-
ations between MPNs and smoking and obesity (for ET patients
only) and identified other potential risk factors including
childhood household crowding and receipt of multiple CT scans.
Childhood circumstances may influence chronic diseases in
later life. Lower childhood SEP has been associated with
increased cancer mortality rates for smoking-related cancers in
some studies potentially mediated in part by lifestyle choices
and SEP in later life.26 When adjusted for potential
confounding factors, including years of formal education,
we identified that lower childhood SEP was associated with an
increased risk of MPNs potentially mediated via similar
mechanisms. Indeed, when we ran a multivariate model with
backwards selection of significant exposure variables, child-
hood household density remained significantly associated with
MPNs. There was also a borderline association between
higher educational attainment and reduced risk of MPNs
which could point towards occupational exposures or lifestyle
risk behaviors.
In keeping with the recentMillionWomen Study18,19 and Iowa
Women’s Health Study20 smoking 20 or more pack years of
cigarettes was associated with an increased risk of MPN in our
study. Supporting the findings from The Iowa Women’s Health
Study we identified that the association with current smoking was
limited to patients with PV.20 As the previous study used medical
claims data, misclassification of cases presenting with secondary
or apparent polycythemia as a result of smoking, may have
occurred.27 In contrast, we had a defined case identification
process ensuring only primary PV patients were included in the
study and confirmed the association was limited to PV cases.
Studies have demonstrated a link between current smoking status
and increased JAK2v617F mutations, potentially through activa-
tion of the JAK pathway via inflammatory processes.28–30 Given
that the majority of PV patients had JAK2v617F mutation present
(94.6%), while only 56.4% and 35.7% of ET and PMF patients
were JAK2v617F positive; this could explain the observed
differences by MPN subgroup. We were unable to confirm this
due to limited power but the ORs were higher compared to
controls for JAK2 positive (OR 2.58) than for JAK2 negative (OR
1.70) cases.
Two cohorts also investigated the association between BMI
and MPNs. In the Million Women Study, obese women had a
33% increased risk of MPNs.19 While we did not observe an
overall statistically significant association we observed a similar
increase in obese individuals. In keeping with our findings, the
Iowa Women’s Study reported that increasing BMI was
associated with a significantly increased risk of ET but not
PV.20 They also reported an increased risk of ET among diabetics
although we did not replicate this in the current study. It has been
speculated that similar pathways may link obesity and
thrombocytosis. In mice studies deletion of Signal transducer
and activator of transcription (STAT)3 in the central nervous
system leads to obesity and diabetes in homozygous mutants31
and deletion of STAT3 in hematopoietic cells enhances
thrombocytosis in JAK2v617F mouse models.
32 The exact
mechanism of action however requires further investigation.
Alcohol was inversely associated with MPNs in this study but
has not previously been associated with MPNs.17–19 Alcohol
Table 5
Association Between Smoking, Alcohol and Body Mass Index and Myeloproliferative Neoplasm (MPN) Subtypes.
Controls Polycythaemia vera Essential thrombocythaemia Primary Myelofibrosis
Variable n (%) n (%) OR (95% CI) n (%) OR (95% CI) n (%) OR (95% CI)
Cigarette smoking
Never 69 (57.5) 18 (48.7) 1.00 28 (50.9) 1.00 5 (35.7) 1.00
Former 45 (37.5) 13 (35.1) 1.06 (0.47–2.41) 25 (45.5) 1.39 (0.71–2.72) 8 (57.1) 1.90 (0.53–6.79)
Current 6 (5.0) 6 (16.2) 3.73 (1.06–13.1) 2 (3.6) 0.86 (0.16–4.59) 1 (7.1) 1.50 (0.11–20.7)
Alcohol
Never 27 (22.5) 15 (40.5) 1.00 22 (40.0) 1.00 4 (28.6) 1.00
Ever 93 (77.5) 22 (59.5) 0.41 (0.19–0.92) 33 (60.0) 0.48 (0.24–0.98) 10 (71.4) 1.03 (0.26–4.11)
Body mass index (current)
Underweight 2 (1.68) 1 (2.7) 1.28 (0.11–15.62) 2 (3.6) 3.16 (0.41–24.2) 0 -
Normal 57 (47.9) 19 (51.4) 1.00 19 (34.6) 1.00 6 (42.9) 1.00
Overweight 45 (37.8) 10 (27.0) 0.61 (0.25–4.62) 22 (40.0) 1.55 (0.73–3.28) 5 (35.7) 0.71 (0.18–2.82)
Obese 15 (12.61) 7 (18.9) 1.38 (0.48–3.94) 12 (21.8) 2.59 (1.02–6.58) 3 (21.4) 1.26 (0.21–7.44)
∗
Adjusted for age (5 year age bands), gender, site location (Southampton/Belfast) and education (category).
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consumption has, however, been inversely associated with other
hematological neoplasms including lymphoma33,34 and leukae-
mia.34 We asked about lifetime alcohol consumption and MPN
patients may have altered their alcohol consumption post-
diagnosis resulting in potential recall bias. While the risk
reduction may be due to reverse causality, resveratrol, found
in red wine, may reduce the risk of lymphoma35 and has been
shown to inhibit proliferation and induce apoptosis in malignant
cell lines with JAK2V617F mutation.
36 We did not observe any
significant differences in MPN risk by alcohol type (wine, beer,
spirits) consumed but sample size was limited. Further evaluation
of the potential interaction between alcohol and the JAK pathway
is warranted.
Painting in decorating at home was inversely associated with
MPNs. While multiple testing could explain this as a chance
association, MPN patients may be less likely to paint due to the
fatigue that they experience from their MPN. While reverse
causation cannot be ruled out we asked whether the patients had
ever painted with the association remaining in the multivariate
model. The strong positive association between pig ownership
and MPNs has not previously been reported. While it is likely a
chance association due to multiple testing, further clarifications
of the association in a larger, suitably powered, study is merited.
Exposure to radiation from CT scans has been reported to
increase the risk of developing a number of cancers including
leukaemia.37 We found that compared with controls, MPN
patients were more likely to have received three or more CT
scans, particularly those with PV. The elevated ORs in our study
may have resulted in part due to the use of CT scans during the
diagnostic work-up or evaluation ofMPNpatients. However, CT
scans are generally not used for PV or ET diagnosis. Further
evaluation of the case clinical notes was not available for
validation and timing of CT scans so we cannot confirm whether
or not all CT scans were pre-diagnosis. If there is a causal
relationship, then the recent introduction of lower dose CT is
likely to reduce the potential carcinogenic effects. Optimization
of the CT image at lower doses and limiting CT scans on the basis
of clinical need is important to reduce potential harmful effects.
Other potential risk factors identified in our previous
systematic review of MPNs included blood donation, dark hair
dye use and some autoimmune conditions.10 Although previous
studies suggested higher PV risk among blood donors,38,39 this
was not substantiated in a recent cohort of 1.4 million blood
donors40 in keeping with the results of the current study. We also
found no association between dark hair dye use and MPNs or
with any of the autoimmune conditions evaluated.
Given the rarity of MPNs, this is the largest case-control study
to date. We evaluated 2 control groups, GP and NBR/F controls,
and found little difference between groups for most variables
assessed. NBR/F controls were more convenient and less
expensive to recruit and are useful for rare diseases where
patients are referred to secondary or tertiary care.41 While it is
acknowledged that there are limitations with this method as it
may lead to closer matching of the case and control populations,
similar characteristics would actually attenuate observed asso-
ciations rather than create erroneous associations.42 Even with
modest numbers, our exploratory study demonstrated significant
differences in several parameters under investigation between
cases andNBR/F controls despite the likelihood of shared factors.
However, our study is likely underpowered to detect small
differences in MPN risk and a large co-ordinated study to
evaluate risk factors associated with MPNs, to enable stratifica-
tion by subtype, is warranted.
In conclusion, this exploratory case-control study confirms a
reported association between cigarette smoking and PV. We also
identified an increased risk of ET in patients defined as obese
according to the WHO classification system. Further investiga-
tion of the relationship between CT scans and alcohol
consumption with MPNs may help in the identification of the
causal pathways that lead to acquisition of acquired mutations
such as JAK2 in patients with MPNs. While this exploratory
study is the largest case-control study ofMPNs reported to date in
the worldwide literature, replication in a larger case-control study
is required to confirm or refute our findings.
Table 6
Medical Conditions and Exposures Compared Between Myelo-
proliferative Neoplasm (MPN) Cases and Controls.
Controls Cases
Variable n (%) n (%) OR
∗
(95% CI)
Rheumatoid Arthritisx
No 118 (98.3) 104 (98.1) 1.00
Yes 2 (1.7) 2 (1.9) 1.12 (0.15–8.32)
Diabetesx
No 113 (94.2) 104 (92.5) 1.00
Yes 7 (5.8) 8 (7.6) 1.33 (0.46–3.82)
Pneumoniax
No 108 (90.0) 96 (90.6) 1.00
Yes 12 (10.0) 8 (7.6) 0.71 (0.27–1.85)
Shinglesx
No 103 (85.8) 95 (92.2) 1.00
Yes 17 (14.2) 8 (7.8) 0.44 (0.17–1.11)
Allergiesx
No 76 (63.3) 77 (72.6) 1.00
Yes 44 (36.7) 29 (27.4) 0.67 (0.38–1.18)
Asthmax
No 101 (84.2) 92 (86.8) 1.00
Yes 19 (15.8) 14 (13.2) 0.82 (0.39–1.74)
Psoriasisx
No 112 (93.3) 103 (97.2) 1.00
Yes 8 (6.7) 3 (2.8) 0.41 (0.11–1.61)
Hypertensionx
No 84 (70.0) 76 (73.1) 1.00
Yes 36 (30.0) 28 (26.9) 0.80 (0.44–1.46)
Heart Diseasex
No 115 (95.8) 98 (92.5) 1.00
Yes 5 (4.2) 8 (7.6) 1.84 (0.57–5.91)
Blood Transfusion
No 95 (80.5) 75 (72.8) 1.00
Yes 23 (19.5) 28 (27.2) 1.56 (0.82–2.97)
X-rays
0–5 22 (18.3) 27 (25.5) 1.00
6-15 52 (43.3) 41 (38.7) 0.64 (0.31–1.33)
>15 46 (38.3) 38 (35.9) 0.65 (0.31–1.39)
CT scans
0 71 (60.2) 53 (52.0) 1.00
1–2 43 (36.4) 33 (32.4) 1.06 (0.59–1.90)
≥3 4 (3.4) 16 (15.7) 5.38 (1.67–17.3)
PV (>3) 4 (3.4) 6 (16.2) 5.62 (1.36–23.2)
ET (>3) 4 (3.4) 5 (9.1) 3.42 (0.82–14.2)
PMF (>3) 4 (3.4) 5 (35.7) 15.3 (2.11–110.5)
Blood Donation
No 59 (49.2) 60 (56.6) 1.00
Yes 61 (50.8) 46 (43.4) 0.78 (0.45–1.33)
Numbers may not add up to the total number of participants as some participants did not know/did not
report if they had ever been diagnosed with the disease in question and were recorded as missing.
∗
Adjusted for age (5 year age bands), gender, site location (Southampton/Belfast), and education
(category).
x Diagnosis pre-MPN diagnosis in cases.
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